Changeflow GovPing Healthcare & Life Sciences Cyr61 in Carbon Nanotubes Restores Bone Density
Routine Notice Added Final

Cyr61 in Carbon Nanotubes Restores Bone Density

Favicon for changeflow.com USPTO Patent Applications - Therapeutics (A61P)
Published
Detected
Email

Summary

The Board of Regents of the University of Texas System has filed Application US20260108472A1 for methods and compositions using recombinant Cyr61 carried in carbon nanotubes to restore Cyr61 expression in bone, increase bone density, and treat bone disease. The application was published April 23, 2026 with inventors Xiao-Dong Chen, Milos Marinkovic, and Qiuxia Dai. No compliance obligations or enforcement actions are associated with this patent application publication.

“Disclosed are methods and compositions for restoring Cyr61 in bone tissue. In certain aspects, the compositions comprise a recombinant Cyr61 carried in carbon nanotubes. The compositions may be used for various methods including restoring Cyr61 expression in bone, increasing bone density, or treating a bone disease in a patient.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.

What changed

The Board of Regents of the University of Texas System has published patent application US20260108472A1 covering recombinant Cyr61 compositions carried in carbon nanotubes for restoring bone density and treating age-related bone loss. The application claims methods for increasing Cyr61 expression in bone tissue and treating bone diseases using the disclosed compositions.

For pharmaceutical and biotechnology companies developing bone disease therapeutics, this published application serves as prior art notice. Competitors should monitor prosecution of this application to assess potential freedom-to-operate implications for their own bone disease programs. The application does not yet grant enforceable patent rights; examination and potential grant would follow.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

REJUVENATING THE AGED SKELETAL MICROENVIRONMENT TO REVERSE AGE-RELATED BONE LOSS

Application US20260108472A1 Kind: A1 Apr 23, 2026

Assignee

THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventors

Xiao-Dong CHEN, Milos MARINKOVIC, Qiuxia DAI

Abstract

Disclosed are methods and compositions for restoring Cyr61 in bone tissue. In certain aspects, the compositions comprise a recombinant Cyr61 carried in carbon nanotubes. The compositions may be used for various methods including restoring Cyr61 expression in bone, increasing bone density, or treating a bone disease in a patient.

CPC Classifications

A61K 9/5115 A61K 38/1709 A61K 38/29 A61P 19/10

Filing Date

2025-09-26

Application No.

19341099

View original document →

Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Docket
US20260108472A1

Who this affects

Applies to
Pharmaceutical companies Biotechnology companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application filing Biotechnology research and development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!